RPG Life Sciences Appoints New CFO, Transfers API Business to Subsidiary
RPG Life Sciences appointed Amol Lone as CFO and KMP, effective December 15, 2025. The company will incorporate a wholly owned subsidiary, "RPG Active Pharma Limited", to house its API business. The API business, contributing ₹90.24 crore revenue, will be transferred for an estimated ₹50 crore. RPG Life Sciences will invest up to ₹105 crore in the subsidiary.
The appointment of a new CFO is a significant management change. The transfer of the API business and the associated investment represent a strategic restructuring that could impact future growth and profitability, making the impact medium.
The appointment of a new CFO and the strategic transfer of the API business to a dedicated subsidiary, along with planned investment, indicates a move towards focused growth and operational efficiency, which is positive for the company.
RPG Life Sciences Limited announced significant corporate developments following its Board of Directors meeting held on December 15, 2025. The company has appointed Mr. Amol Lone as the Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective from the same date. Mr. Lone brings over two decades of experience in corporate finance, financial planning, taxation, and strategic decision-making, holding qualifications as a Chartered Accountant and an MBA in International Business.
Furthermore, the Board approved the incorporation of a new wholly owned subsidiary, to be named "RPG Active Pharma Limited" or a similar approved name. This subsidiary will focus on the manufacture and marketing of active pharmaceutical ingredients (API) and related pharmaceutical products. The company also resolved to transfer its existing API business to this new subsidiary as a going concern, subject to necessary statutory and regulatory approvals.
RPG Life Sciences plans to invest up to ₹105 crore in the new subsidiary in tranches for capitalization and business operations. The API business transferred contributed approximately ₹90.24 crore in revenue (13.8% of FY25 turnover) and had a net worth of ₹90.61 crore as of March 31, 2025. The consideration for the transfer of the API business is expected to be around ₹50 crore, with the business transfer agreement anticipated to be executed by February 28, 2026, and the transfer completion targeted by March 31, 2026. The meeting commenced at 02:00 p.m. and concluded at 3.10 p.m.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.